Resources
13 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/11/2022 (updated 4/11/2024)
This packet presents Implementation III grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 3/25/2021 (updated 4/5/2024)
Care Coordination: Navigating Individuals With OUD Through a Treatment and Recovery Continuum
Presenters from the Western Region will describe two innovative care coordination strategies and models from the RCORP/Rural Health Opioid Program grantee perspective.
Posted 9/1/2021 (updated 4/2/2024)
Deliverable Guidance: PIMS
Kathleen Meyers, PhD, and Rebecca Schachtner, PhD, JBS International
Posted 9/1/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session for RCORP Implementation and MAT Expansion grantees was held in the Monument Room on Friday, March 6, 2020, at 11:15 AM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Monument Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Mt. Vernon Square Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 7/26/2023 (updated 3/28/2024)
Sonoran Prevention Works (SPW) shared some of its experiences implementing harm reduction in Cochise County, one of the more rural counties in AZ. SPW provides street-based outreach, testing, and peer support; offers training, education, and technical assistance and TA; and engages in local and state advocacy work.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.